Blackstone Inc
CNTA

Blackstone Inc’s Centessa Pharmaceuticals CNTA Stock Holding History

Blackstone Inc’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-40,000
Closed -$888K – 627
2021
Q2 		$888K Buy
+40,000
New +$940K ﹤0.01% 394

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Blackstone Inc's CNTA Position: Q3 2021 in Review

Blackstone Inc sold out of Centessa Pharmaceuticals (CNTA) in Q3 2021, closing a stake of 40,000 shares — an estimated $888K sold.

Blackstone Inc first reported a position in CNTA in Q2 2021 and held it in 1 quarter. The position peaked at $888K in Q2 2021. 40 funds tracked by Wall St. Rank hold CNTA as of Q3 2021.

  • Blackstone Inc reported no remaining Centessa Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Blackstone Inc sold 40,000 Centessa Pharmaceuticals shares in Q3 2021, an estimated $888K.
  • Blackstone Inc first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Blackstone Inc's Centessa Pharmaceuticals position peaked at $888K in Q2 2021.
  • 40 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q3 2021.

Based on Blackstone Inc's 13F filing for Q3 2021, filed 16 Nov 2021.